Like/Tweet/+1
Search
Display results as :
Advanced Search
RSS feeds

Yahoo! 
MSN 
AOL 
Netvibes 
Bloglines 
Social bookmarking
Social bookmarking Digg  Social bookmarking Delicious  Social bookmarking Reddit  Social bookmarking Stumbleupon  Social bookmarking Slashdot  Social bookmarking Yahoo  Social bookmarking Google  Social bookmarking Blinklist  Social bookmarking Blogmarks  Social bookmarking Technorati  




Bookmark and share the address of UKRAINE ENGLISH NEWS on your social bookmarking website

Share
View previous topicView next topic
avatar
Admin
Administrator
Posts : 13042
Join date : 2015-05-20
Location : United States
http://www.ukraineenglishnews.com
20160629
Management of sanitary inspection by the Food and Drug Administration (FDA) has allowed use in medicine cure Epclusa.

Reported Tech Insider .

Medicines are struggling right of all known strains of hepatitis C and provide almost 100% of the first effects after 3 months of regular use.

Epclusa has sofosbuvir and velpatasvira. Both substances have been developed biopharmaceutical company Gilead Sciences. Sofosbuvir been approved for use in 2013 and received permission velpatasvir FDA only recently.

In a world suffering from hepatitis 130-150 million people. The disease is divided into six major genotypes, or strains, based on which doctors picked by appropriate treatment. Epclusa just struggling with all kinds of hepatitis C. The patient need only take one tablet daily for 12 weeks.

After receiving Epclusa in 95-99% of patients with cirrhosis has not yet developed or is in the early stages of the virus in the blood was found. Patients with serious disorders of the liver Epclusa used together with ribavirin treatment and the percentage was 94%.

Cure Gilead will be available through a few great prices. Epclusa course will cost $ 74,760. This is $ 10,000 cheaper medicines on the basis of only sofosbuvir.

ukr.obozrevatel.com   In Ukrainian/український
Share this post on:Excite BookmarksDiggRedditDel.icio.usGoogleLiveSlashdotNetscapeTechnoratiStumbleUponNewsvineFurlYahooSmarking

Comments

No Comment.

View previous topicView next topic
Permissions in this forum:
You cannot reply to topics in this forum